Ublituximab (TG-1101), A Novel Glycoenginereed Anti-CD20 mAb, in Combination with Ibrutinib in Patients with CLL and MCL; Results of an Ongoing Phase II Trial.

Drug Category : Array
Conference Category : Array
Lead Author : Sharman J, O'Connor O, et. al.
Published Date : 13/06/2014
Download Link : https://www.tgtherapeutics.com/wp-content/uploads/2019/03/EHA2014-PosterP880.PDF
Download Text : Download
Popup Confirmation? :
site-sidebar-layout : default
ast-site-content-layout : default
site-content-style : default
site-sidebar-style : default
theme-transparent-header-meta : default
stick-header-meta : default
astra-migrate-meta-layouts : set
Scroll to Top